
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac SSO110
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Details : 225-Ac SSO110 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : 225-Ac SSO110
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

U.S. FDA Grants Orphan Drug Designation to Ariceum's Radiopharmaceutical Cancer Therapy
Details : 225Ac-SSO110 (225-Ac satoreotide tetraxetan) is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 , it is being investigated in in patients with small cell lung cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 06, 2025

FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide for Small Cell Lung Cancer
Details : 225Ac-SSO110 is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 , it is being investigated in in patients with small cell lung cancer or merkel cell carcinoma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac Satoreotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Agreement
ITM, Ariceum Enter Supply Agreement for Actinium-225 Medical Radioisotope
Details : Under the terms of the agreement, ITM will supply the therapeutic medical radioisotope, Ac-225 to advance the clinical development of SSO110 (225Ac-satoreotide tetraxetan) for treatment of neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : 225-Ac Satoreotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Isotope Technologies Munich
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac Satoreotide Trizoxetan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Agreement
Ariceum, NorthStar Partner On Actinium-225 Supply for Therapeutic Use
Details : Under the agreement, NorthStar will provide Ariceum with an Ac-225 radiolabelled compound. Ariceum will further develop SS0110 (Ac-225-satoreotide trizoxetan) for the treatment of SCLC.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : 225-Ac Satoreotide Trizoxetan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : NorthStar Medical Radioisotopes
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177Lu-Satoreotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Eckert & Ziegler Strahlen
Deal Size : Undisclosed
Deal Type : Agreement
Ariceum, Eckert Sign Agreement for Radiotherapeutics Cancer Treatments
Details : Eckert & Ziegler will supply Ariceum with n.c.a. Ac-225 and Lu-177 used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug SS0110 (satoreotide) targeting hard-to-treat cancers.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : 177Lu-Satoreotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Eckert & Ziegler Strahlen
Deal Size : Undisclosed
Deal Type : Agreement

Ariceum Therapeutics Starts Phase 1 Trial in Patients with Recurrent Glioblastoma
Details : 123I-ATT001, is an Iodine-123 labelled PARP inhibitor, which is being investigated in patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Granted UK Authorisation for Phase I Study of Iodine-123 in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Files for UK CTA for Iodine-123 PARP Inhibitor in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 177Lu-OPS201 (satoreotide) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
